{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:38:55Z","timestamp":1779223135681,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40272-024-00657-3","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T09:01:43Z","timestamp":1728118903000},"page":"767-785","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adverse Event Profile of First-line Drugs for Treating Patent Ductus Arteriosus in Neonates: A Disproportionality Analysis Study of USFDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowri","family":"Sivaramakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"issue":"6","key":"657_CR1","doi-asserted-by":"publisher","first-page":"F505","DOI":"10.1136\/archdischild-2013-303816","volume":"98","author":"A Sellmer","year":"2013","unstructured":"Sellmer A, Bjerre JV, Schmidt MR, McNamara PJ, Hjortdal VE, H\u00f8st B, Bech BH, Henriksen TB. Morbidity and mortality in preterm neonates with patent ductus arteriosus on day 3. Arch Dis Child Fetal Neonatal Ed. 2013;98(6):F505\u201310.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"17","key":"657_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.025784","volume":"11","author":"CH Backes","year":"2022","unstructured":"Backes CH, Hill KD, Shelton EL, Slaughter JL, Lewis TR, Weisz DE, Mah ML, Bhombal S, Smith CV, McNamara PJ, Benitz WE, Garg V. Patent ductus arteriosus: a contemporary perspective for the pediatric and adult cardiac care provider. J Am Heart Assoc. 2022;11(17): e025784.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"657_CR3","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.1038\/s41598-021-89868-z","volume":"11","author":"J Park","year":"2021","unstructured":"Park J, Yoon SJ, Han J, Song IG, Lim J, Shin JE, Eun HS, Park KI, Park MS, Lee SM. Patent ductus arteriosus treatment trends and associated morbidities in neonates. Sci Rep. 2021;11(1):10689.","journal-title":"Sci Rep"},{"issue":"3","key":"657_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000526318","volume":"7","author":"S Eursiriwan","year":"2022","unstructured":"Eursiriwan S, Okascharoen C, Vallibhakara SA, Pattanaprateep O, Numthavaj P, Attia J, Thakkinstian A. Comparison of various pharmacologic agents in the management of hemodynamically significant patent ductus arteriosus in preterm: a network meta-analysis and risk-benefit analysis. Biomed Hub. 2022;7(3):125\u201345.","journal-title":"Biomed Hub."},{"key":"657_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104418","volume":"148","author":"E Marconi","year":"2019","unstructured":"Marconi E, Bettiol A, Ambrosio G, Perduca V, Vannacci A, Troiani S, Dani C, Mugelli A, Lucenteforte E. Efficacy and safety of pharmacological treatments for patent ductus arteriosus closure: a systematic review and network meta-analysis of clinical trials and observational studies. Pharmacol Res. 2019;148: 104418.","journal-title":"Pharmacol Res"},{"issue":"5","key":"657_CR6","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cpt.2172","volume":"109","author":"A Lavertu","year":"2021","unstructured":"Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clin Pharmacol Ther. 2021;109(5):1197\u2013202.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"657_CR7","first-page":"771","volume":"63","author":"JE Campbell","year":"2014","unstructured":"Campbell JE, Gossell-Williams M, Lee MG. A review of pharmacovigilance. West Indian Med J. 2014;63(7):771\u20134.","journal-title":"West Indian Med J"},{"issue":"Suppl 1","key":"657_CR8","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.4103\/0976-500X.120955","volume":"4","author":"C Palleria","year":"2013","unstructured":"Palleria C, Leporini C, Chimirri S, Marrazzo G, Sacchetta S, Bruno L, Lista RM, Staltari O, Scuteri A, Scicchitano F, Russo E. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two \u201cchallenging\u201d case reports. J Pharmacol Pharmacother. 2013;4(Suppl 1):S66-72.","journal-title":"J Pharmacol Pharmacother"},{"key":"657_CR9","unstructured":"Potential Signals of Serious Risks\/New Safety Information Identified from the FDA Adverse Event Reporting System (FAERS). Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/potential-signals-serious-risksnew-safety-information-identified-fda-adverse-event-reporting-system (Accessed on 18th June 2024)."},{"issue":"3","key":"657_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247446","volume":"16","author":"S Leitzen","year":"2021","unstructured":"Leitzen S, Dubrall D, Toni I, Stingl J, Schulz M, Schmid M, Neubert A, Sachs B. Analysis of the reporting of adverse drug reactions in children and adolescents in Germany in the time period from 2000 to 2019. PLoS ONE. 2021;16(3): e0247446.","journal-title":"PLoS ONE"},{"issue":"2","key":"657_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4103\/jpbs.jpbs_420_22","volume":"15","author":"K Sridharan","year":"2023","unstructured":"Sridharan K, Madhoob AA, Jufairi MA, Ansari EA, Marzooq RA, Hubail Z, Hasan SJ. Gentamicin in neonates with hemodynamically significant patent ductus arteriosus. J Pharm Bioallied Sci. 2023;15(2):95\u2013100.","journal-title":"J Pharm Bioallied Sci."},{"issue":"2","key":"657_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40272-016-0165-5","volume":"18","author":"S Sivanandan","year":"2016","unstructured":"Sivanandan S, Agarwal R. Pharmacological closure of patent ductus arteriosus: selecting the agent and route of administration. Paediatr Drugs. 2016;18(2):123\u201338.","journal-title":"Paediatr Drugs"},{"key":"657_CR13","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. Available at: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (Accessed on 14th June 2024)."},{"issue":"2","key":"657_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225\u201332.","journal-title":"Therapie"},{"issue":"8","key":"657_CR15","first-page":"138","volume":"10","author":"G Park","year":"2020","unstructured":"Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance. Life (Basel). 2020;10(8):138.","journal-title":"Life (Basel)."},{"issue":"6","key":"657_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"657_CR17","unstructured":"Practical aspects of signal detection in pharmacovigilance. Report of CIOMS working group VIII. Geneva. Available at: https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf (Accessed on August 19, 2024)."},{"key":"657_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-3-642-00663-0_12","volume":"196","author":"JA Hinson","year":"2010","unstructured":"Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;196:369\u2013405.","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"657_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1084-2756(03)00066-6","volume":"8","author":"SV Beath","year":"2003","unstructured":"Beath SV. Hepatic function and physiology in the newborn. Semin Neonatol. 2003;8(5):337\u201346.","journal-title":"Semin Neonatol."},{"issue":"4","key":"657_CR20","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/pr.2017.129","volume":"82","author":"RB Flint","year":"2017","unstructured":"Flint RB, Roofthooft DW, van Rongen A, van Lingen RA, van den Anker JN, van Dijk M, Allegaert K, Tibboel D, Knibbe CAJ, Simons SHP. Exposure to acetaminophen and all its metabolites upon 10, 15, and 20 mg\/kg intravenous acetaminophen in very-preterm infants. Pediatr Res. 2017;82(4):678\u201384.","journal-title":"Pediatr Res"},{"issue":"1","key":"657_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13052-021-00956-2","volume":"47","author":"G Terrin","year":"2021","unstructured":"Terrin G, Di Chiara M, Boscarino G, Metrangolo V, Faccioli F, Onest\u00e0 E, Giancotti A, Di Donato V, Cardilli V, De Curtis M. Morbidity associated with patent ductus arteriosus in preterm newborns: a retrospective case-control study. Ital J Pediatr. 2021;47(1):9.","journal-title":"Ital J Pediatr"},{"key":"657_CR22","unstructured":"Acetaminophen. Summary of product characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/5164\/smpc\/print (accessed on 11th August 2024)."},{"key":"657_CR23","unstructured":"Ibuprofen. Summary of product characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/3876\/smpc\/print (accessed on 11th August 2024)."},{"key":"657_CR24","unstructured":"Indomethacin. Summary of product characteristics. Available at: https:\/\/www.medicines.org.uk\/emc\/product\/2946\/smpc\/print (accessed on August 11, 2024)."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-024-00657-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-024-00657-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T15:05:17Z","timestamp":1730127917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-024-00657-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s40272-024-00657-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"15 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Kannan Sridharan and Gowri Sivaramakrishnan declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"KS: Conceived the idea. KS and GS: Data curation, analysis and interpretation. KS: Wrote the first draft of the manuscript. KS and GS: Involved in critical revisions and final acceptance of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}